Table 1. Baseline Characteristics of Patients With Localized Prostate Cancer Included in Analysis Examining Patient-Reported Regret at 5 Years After Diagnosis, Stratified by Initial Treatment Approach.
| Characteristic | Treatment groupa | P value | |||
|---|---|---|---|---|---|
| Surgery (n = 1136) | Radiotherapy (n = 667) | Active surveillance (n = 269) | All (N = 2072) | ||
| Age at diagnosis, median (IQR), y | 62 (57-67) | 68 (63-73) | 66 (60-71) | 64 (59-69) | <.001 |
| Race and ethnicity | |||||
| Asian | 38 (3) | 17 (3) | 9 (3) | 64 (3) | .03 |
| Black | 116 (10) | 103 (15) | 34 (13) | 253 (12) | |
| Hispanic | 96 (8) | 39 (6) | 15 (6) | 150 (7) | |
| White | 870 (77) | 498 (75) | 205 (76) | 1573 (76) | |
| Otherb | 15 (1) | 10 (1) | 6 (2) | 31 (1) | |
| Educational level | |||||
| Less than high school | 92 (8) | 67 (11) | 17 (7) | 176 (9) | .20 |
| High school graduate | 209 (19) | 122 (19) | 40 (16) | 371 (19) | |
| Some college | 241 (22) | 147 (23) | 52 (20) | 440 (22) | |
| College graduate | 267 (24) | 149 (23) | 65 (25) | 481 (24) | |
| Graduate/professional school | 292 (27) | 153 (24) | 83 (32) | 528 (26) | |
| Marital status | |||||
| Not married | 178 (16) | 149 (23) | 53 (21) | 380 (19) | .001 |
| Married | 921 (81) | 490 (77) | 203 (79) | 1614 (79) | |
| TIBIc | |||||
| 0-2 | 397 (36) | 143 (22) | 74 (29) | 614 (31) | <.001 |
| 3-4 | 470 (43) | 266 (41) | 107 (42) | 843 (42) | |
| ≥5 | 237 (21) | 233 (36) | 76 (30) | 546 (27) | |
| D’Amico risk category | |||||
| Low | 494 (44) | 246 (37) | 211 (78) | 951 (46) | <.001 |
| Intermediate | 460 (41) | 284 (43) | 50 (19) | 794 (38) | |
| High | 180 (16) | 134 (20) | 7 (3) | 321 (16) | |
| PSA level at diagnosis, corrected, median (IQR), ng/mL | 5 (4-7) | 6 (4-8) | 5 (4-7) | 5 (4-7) | <.001 |
| PSA level at diagnosis, corrected, ng/mL | |||||
| <4 | 234 (21) | 98 (15) | 70 (26) | 402 (19) | <.001 |
| ≥4-10 | 787 (69) | 478 (72) | 166 (62) | 1431 (69) | |
| ≥10-20 | 86 (8) | 68 (10) | 29 (11) | 183 (9) | |
| ≥20-50 | 29 (3) | 23 (3) | 4 (1) | 56 (3) | |
| Clinical tumor stage | |||||
| T1 | 850 (75) | 496 (74) | 224 (85) | 1570 (76) | .002 |
| T2 | 285 (25) | 170 (25) | 40 (15) | 495 (24) | |
| Biopsy Gleason scored | |||||
| ≤6 | 570 (50) | 275 (41) | 236 (88) | 1081 (52) | <.001 |
| 3 + 4 | 336 (30) | 221 (33) | 27 (10) | 584 (28) | |
| 4 + 3 | 121 (11) | 76 (11) | 3 (1) | 200 (10) | |
| 8, 9, 10 | 105 (9) | 92 (14) | 2 (1) | 199 (10) | |
| Risk status | |||||
| Favorable | 848 (75) | 466 (70) | 258 (96) | 1572 (76) | <.001 |
| Unfavorable | 285 (25) | 198 (30) | 10 (4) | 493 (24) | |
| Any ADT in year 1 | |||||
| No | 1082 (96) | 451 (68) | 249 (93) | 1782 (87) | <.001 |
| Yes | 48 (4) | 211 (32) | 1 (0.4) | 260 (13) | |
| Received pelvic radiotherapy | |||||
| Yes | 14 (25) | 80 (13) | 0 | 94 (14) | .05 |
| No | 42 (75) | 515 (87) | 2 (100) | 559 (86) | |
| Site | |||||
| Utah | 112 (10) | 58 (9) | 42 (16) | 212 (10) | <.001 |
| Atlanta, Georgia | 143 (13) | 144 (21) | 31 (11) | 318 (15) | |
| Los Angeles, California | 367 (32) | 150 (22) | 104 (39) | 621 (30) | |
| Louisiana | 310 (27) | 186 (28) | 67 (25) | 563 (27) | |
| New Jersey | 204 (18) | 129 (19) | 25 (9) | 358 (17) | |
Abbreviations: ADT, androgen deprivation therapy; PSA, prostate-specific antigen; TIBI, Total Illness Burden Index.
a
Unless otherwise indicated, data are expressed as number (%) of patients. Percentages have been rounded and may not sum to 100. Owing to missing data, numbers may not sum to the totals in the column headings.
b
Includes American Indian/Alaska Native as well as those who responded “other” to indicate that their race or ethnicity was not included on the list of options defined by Census criteria.
c
Scores range from 0 to 23, with higher scores indicating greater severity and number of comorbid illnesses.
d
Scores range from 2 to 10 theoretically, but practically from 6 to 10, with higher scores indicating higher-grade disease.